Patients with fibromyalgia (FM) report sustained improvements in their health-related quality-of-life following the use of medical cannabis preparations, according to observational data published in the journal Clinical Rheumatology.
British investigators assessed the adjunctive use of cannabis-based medicinal products (CBMPs) in a cohort of 497 FM patients enrolled in the UK Medical Cannabis Registry. Patients’ outcomes were assessed at baseline and at one, three, six, twelve and eighteen months. Study participants consumed either herbal cannabis or oil extracts containing standardised concentrations of THC and CBD.
Consistent with previous studies, patients reported long-term improvements in their pain, anxiety, sleep and overall quality-of-life following cannabis treatment. “CBMPs were associated with improvements in all PROMs [patient-reported outcome measures], fibromyalgia-specific and general-health related, from baseline to all follow-up measures at 1, 3, 6, 12, and 18 months”, the study’s authors concluded.
19 December, 2025